Rationale of Using Common Antifibrotic Therapy in Post COVID Fibrosis.

BYM Sinaga, AH Tarigan - Open Access Macedonian Journal of Medical …, 2022 - oamjms.eu

BACKGROUND: The pandemic that occurred at the end of 2019 was caused by the
coronavirus 2 (Severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]). Various …

Management of Pulmonary Fibrosis from COVID-19 Pneumonia with Nintedanib

S Saenghirunvattana, T Saksirinukul… - The Bangkok …, 2022 - he02.tci-thaijo.org

OBJECTIVES: To propose the benefit of antifibrotic agent, nintedanib, in the treatment of
lung fibrosis from SARS-CoV-2 Coronavirus 2019 (COVID-19) pneumonia, based on …

[PDF] researchgate.net

[PDF][PDF] Use of Nintedanib and its Outcome among Post-COVID Pulmonary Fibrosis Patients Residing at High Altitudes: A Case Series

A Pal, AK Mishra, MK Yadav, RM Giri… - … Rep Jour. 2023; 2 (18): 1 - researchgate.net

Introduction: The purpose of this study was to determine the effect of nintedanib among
critically ill COVID-19 patients and to assess its effect on their clinical status and radiological …

[PDF][PDF] Lung Fibrosis due to Coronavirus Disease 2019 Pneumonia with Critical Symptoms: A Case Report. Open Access Maced J Med Sci. 2022 Jan 08; 10 (C): 1-5

BYM Sinaga, AH Tarigan - 2022 - academia.edu

BACKGROUND: The pandemic that occurred at the end of 2019 was caused by the
coronavirus 2 (Severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]). Various …

[PDF] unican.es

Preliminary steps in the analysis of the protective potential of plant extracts against SARS-CoV-2 infection in lung cells

AC Chambers - 2021 - repositorio.unican.es

The SARS-CoV-2 pandemic is without doubt one of the greatest challenges modern
medicine has ever faced. To date there is still no cure and effective treatments are …